J. Bergman

发表

Kinesin spindle protein (KSP) inhibitors. Part 7: Design and synthesis of 3,3-disubstituted dihydropyrazolobenzoxazines as potent inhibitors of the mitotic kinesin KSP.

Youwei Yan, P. Coleman, L. Kuo, 2007, Bioorganic & medicinal chemistry letters.

Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia.

Steven V. Fox, John D. Schreier, J. Renger, 2014, Bioorganic & medicinal chemistry letters.

4-Oxospiro[benzopyran-2,4′-piperidines] as selective α1a-adrenergic receptor antagonists

M. Bock, R. Chang, T. Broten, 1999 .

Design and synthesis of N-alkylated saccharins as selective α-1a adrenergic receptor antagonists☆

R. Chang, Tsing-bau Chen, J. Huff, 1998 .

Selective non-peptide ligands for an accommodating peptide receptor. Imidazobenzodiazepines as potent cholecystokinin type B receptor antagonists.

J. Kemp, D. Veber, M. Bock, 1994, Bioorganic & medicinal chemistry.

Oxo-piperazine derivatives of N-arylpiperazinones as inhibitors of farnesyltransferase.

J. Davide, N. Kohl, R. Lobell, 2001, Bioorganic & medicinal chemistry letters.

Proline bis-amides as potent dual orexin receptor antagonists.

J. Renger, P. Coleman, D. Reiss, 2008, Bioorganic & medicinal chemistry letters.

TANDEM REDUCTIVE ALKYLATION-CYCLIZATION FOR THE PREPARATION OF UNSYMMETRICAL 1,4-DISUBSTITUTED 2,3-DIKETOPIPERAZINES

C. Dinsmore, J. Bergman, 1998 .

Aryloxy substituted N-arylpiperazinones as dual inhibitors of farnesyltransferase and geranylgeranyltransferase-I.

J. Davide, N. Kohl, R. Lobell, 2001, Bioorganic & medicinal chemistry letters.

3,8-Diazabicyclo[3.2.1]octan-2-one peptide mimetics: synthesis of a conformationally restricted inhibitor of farnesyltransferase.

M. Bogusky, J. Culberson, C. Dinsmore, 2001, Organic letters.

N-arylpiperazinone inhibitors of farnesyltransferase: discovery and biological activity.

J. Huff, J. Davide, N. Kohl, 1999, Journal of medicinal chemistry.

Conformational restriction of flexible ligands guided by the transferred noe experiment: potent macrocyclic inhibitors of farnesyltransferase.

J. Huff, M. Bogusky, S. Graham, 2001, Journal of the American Chemical Society.